Skip to main content
. 2016 Apr 7;89(1062):20150966. doi: 10.1259/bjr.20150966

Table 4.

Comparative evaluation of baseline (pre-T/t) and post treatment (post-T/t) quality of life parameters [according to the European Organisation for Research and Treatment of Cancer quality of life questionnaire (QLQ) C30 and LC13]

Parameters Arm A, median (range) Arm B, median (range) p-value
Global health status
 Pre-T/t 41.67 (0–58.33) 50 (8.33–66.67) 0.24
 Post-T/t 58.33 (8.33–100) 66.67 (41.67–100) 0.44
Physical functioning
 Pre-T/t 53.33 (6.67–100) 73.33 (13.33–100) 0.13
 Post-T/t 73.33 (0–80) 80 (53.33–100) 0.14
Role functioning
 Pre-T/t 50 (0–100) 83.33 (0–100) 0.12
 Post-T/t 83.33 (0–100) 100 (66.67–100) 0.25
Emotional functioning
 Pre-T/t 53.33 (16.67–100) 41.67 (8.33–100) 0.81
 Post-T/t 66.67 (16.67–100) 91.66 (41.66–100) 0.009
Cognitive functioning
 Pre-T/t 66.67 (16.67–100) 83.33 (16.67–100) 0.41
 Post-T/t 75 (33.33–100) 100 (50–100) 0.04
Social functioning
 Pre-T/t 66.67 (0–100) 83.33 (0–100) 0.93
 Post-T/t 66.67 (0–100) 100 (33.33–100) 0.07
Fatigue
 Pre-T/t 66.67 (0–100) 44.33 (0–100) 0.21
 Post-T/t 33.33 (11–88.9) 22.33 (0–100) 0.37
Nausea and vomiting
 Pre-T/t 0 (0–66.67) 16.67 (0–66.67) 0.41
 Post-T/t 0 (0–66.67) 0 (0–33.33) 0.84
Pain
 Pre-T/t 50 (0–100) 33.33 (0–100) 0.52
 Post-T/t 33.33 (0–66.67) 33.33 (0–83.33) 0.19
Dyspnoea according to QLQ C30
 Pre-T/t 33.33 (0–100) 33.33 (0–100) 0.19
 Post-T/t 16.67 (0–100) 33.33 (0–33.33) 0.83
Insomnia
 Pre-T/t 33.33 (0–100) 33.33 (0–66.67) 0.49
 Post-T/t 0 (0–66.67) 33.33 (0–66.67) 0.77
Anorexia
 Pre-T/t 66.67 (0–100) 66.67 (0–100) 0.99
 Post-T/t 33.33 (0–100) 33.33 (0–100) 0.63
Constipation
 Pre-T/t 0 (0–33.33) 0 (0–66.67) 0.99
 Post-T/t 0 (0–66.67) 0 (0–66.67) 0.44
Diarrhoea
 Pre-T/t 0 (0–33.33) 0 (0–33.33) 0.83
 Post-T/t 0 0 0.99
Financial difficulty
 Pre-T/t 66.67 (0–100) 66.67 (0–100) 0.66
 Post-T/t 66.67 (0–100) 33.33 (0–66.67) 0.23
Dyspnoea according to LC13
 Pre-T/t 33.33 (0–100) 33.33 (0–88.9) 0.44
 Post-T/t 33.33 (11.1–100) 22.23 (0–55.67) 0.29
Cough according to LC13
 Pre-T/t 33.33 (0–100) 33.33 (33.33–100) 0.60
 Post-T/t 33.33 (0–66.67) 33.33 (0–66.67) 0.62
Haemoptysis according to LC13
 Pre-T/t 0 (0–100) 0 (0–100) 0.87
 Post-T/t 0 (0–33.33) 0 (0–33.33) 0.88
Soreness of mouth according to LC13
 Pre-T/t 0 (0–66.67) 0 (0–66.67) 0.27
 Post-T/t 0 (0–33.33) 0 (0–33.33) 0.67
Dysphagia according to LC13
 Pre-T/t 0 (0–66.67) 0 (0–100) 0.75
 Post-T/t 0 (0–66.67) 0 (0–33.33) 0.48
Peripheral neuropathy according to LC13
 Pre-T/t 0 (0–66.67) 0 (0–66.67) 0.99
 Post-T/t 66.67 (0–66.67) 66.67 (0–100) 0.86
Alopecia according to LC13
 Pre-T/t 0 0 0.99
 Post-T/t 33.33 (0–66.67) 66.67 (0–100) 0.09
Pain chest according to LC13
 Pre-T/t 33.33 (0–100) 33.33 (0–100) 0.82
 Post-T/t 66.67 (0–100) 0 (0–66.67) 0.04
Pain in arm according to LC13
 Pre-T/t 33.33 (0–66.67) 33.33 (0–100) 0.32
 Post-T/t 16.67 (0–66.67) 0 (0–66.67) 0.52
Pain in other parts according to LC13
 Pre-T/t 33.33 (0–100) 33.33 (0–100) 0.62
 Post-T/t 0 (0–66.67) 0 (0–66.67) 0.23

Bold values indicate significance on statistical analyses.